Drug Repurposing: Testing a Drug Approved for One Disease for Its Efficacy in Another

This is an archived file of an event that took place on July 20,2017

In this webinar, we talk about why we need to test these drugs in Parkinson's, how they're identified and go through some in the pipeline.

Title: Drug Repurposing: Testing a Drug Approved for One Disease for Its Efficacy in Another
Duration: 1 hour

Continuing Medical Education Information for Health Care Professionals

MJFF offers Continuing Medical Education (CME) credit for practicing health care professionals for each Third Thursday Webinar. Click the link in the Resource List after viewing the webinar to take the post-test survey and receive your CME credit.

Date of Original Release: July 20, 2017
Date CME Credit No Longer Available: July 20, 2019

Learning Objectives
At the conclusion of this course, participants should be able to: 

  1. Define drug repurposing. 
  2. Describe how drugs are chosen for repurposing. 
  3. Discuss why drugs need to be tested in a new patient population. 
  4. Summarize where repurposed drugs are in clinical testing for Parkinson's disease.

Target Audience
This educational activity is designed for primary care physicians, family practice physicians, general medicine physicians, geriatricians, general neurologists, movement disorder specialists and any other health care practitioners who manage patients with Parkinson's disease.

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Oakstone Publishing, LLC and The Michael J. Fox Foundation for Parkinson's Research. The Oakstone Publishing, LLC is accredited by the ACCME to provide continuing medical education for physicians.

Oakstone Publishing, LLC designates this enduring material for a maximum of 1.0 AMA PRA Category 1 CreditsTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Oakstone Publishing, LLC has assessed conflict of interest with its faculty, authors, editors and any individuals who were in a position to control the content of this CME activity. Any identified relevant conflicts of interest were resolved for fair balance and scientific objectivity of studies utilized in this activity. Oakstone Publishing, LLC's planners, content reviewers, and editorial staff disclose no relevant commercial interests.

Dave Iverson
Nothing to disclose

Todd Sherer, PhD
Chief Executive Officer
The Michael J. Fox Foundation
Wife is employed at Pfizer

Sabrina Paganoni
Assistant Professor
Harvard Medical School
Nothing to disclose


Already Registered?

*Required Fields.

You must have Javascript and Cookies enabled to access this webcast. Click here for Help.

By registering you agree to receive email updates from
The Michael J. Fox Foundation. You can unsubscribe any time.